Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv CD28 CD3ζ recombinant gene

• Published in: Leukemia & lymphoma Vol. 49; no. 7; pp. 1368 - 1373
• Main Authors: Yu, Kang, Hu, Yongxian, Tan, Yinxia, Shen, Zhijian, Jiang, Songfu, Qian, Honglan, Liang, Bin, Shan, Daming
• Format: Journal Article
• Language: English
• Published: Informa UK Ltd 01.01.2008; Taylor & Francis
• Subjects: anti-CD20 antibody; CD28; CD3; Cellular immunotherapy; lymphoma; scFv
• ISSN: 1042-8194; 1029-2403
• DOI: 10.1080/10428190802064958

One of the approaches to make anti-CD20 antibody more efficient is to express this antibody on the surface of T cells. scFv from anti-CD20 antibody has been expressed on T cell surface to bind to CD20 positive cells and CD3ζ has been expressed as a fusion partner to transduct signals. T cells grafted with this chimeric scFv CD3ζ were able to redirect grafted T cells to an MHC Ag-independent antitumor response. To test the effects of CD28 signal on the cellular activation and antitumor effectiveness of chimeric scFv CD3ζ modified T cells, we constructed a recombinant anti-CD20 scFv CD28 CD3ζ gene in a retroviral vector. T cells expressing anti-CD20 scFv CD28 CD3ζ specifically lysed CD20 positive target tumor cells and secreted not only IFN-γ but also IL-2 after binding to their target cells. Our data indicate that CD3 and CD28 signalling can be delivered in one molecule, which is sufficient for complete T cell activation without exogenous B7 CD28 costimulation.